CA2354779A1 - Inhibiteurs de la farnesyl proteine transferase tryciclique - Google Patents

Inhibiteurs de la farnesyl proteine transferase tryciclique Download PDF

Info

Publication number
CA2354779A1
CA2354779A1 CA002354779A CA2354779A CA2354779A1 CA 2354779 A1 CA2354779 A1 CA 2354779A1 CA 002354779 A CA002354779 A CA 002354779A CA 2354779 A CA2354779 A CA 2354779A CA 2354779 A1 CA2354779 A1 CA 2354779A1
Authority
CA
Canada
Prior art keywords
alkyl
substituted
aryl
arylalkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002354779A
Other languages
English (en)
Inventor
Arthur G. Taveras
Ronald J. Doll
Alan B. Cooper
Johan A. Ferreira
Timothy Guzi
Alan K. Mallams
Dinanath F. Rane
Viyyoor M. Girijavallabhan
Adriano Afonso
Cynthia J. Aki
Jianping Chao
Carmen Alvarez
Joseph M. Kelly
Tarik Lalwani
Jagdish A. Desai
James J.S. Wang
Jay Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2354779A1 publication Critical patent/CA2354779A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)

Abstract

L'invention concerne des composés de formule (1.0) dans laquelle R?13¿ représente un cycle imidazole; R?14¿ représente un carbamate, urée, amide ou un groupe sulfonamide; R?8¿ représente H lorsque la chaîne alkyle entre le groupe amide et le groupe imidazole R?13¿ est substituée ou R?8¿ représente un substituant, à savoir un arylalkyle, hétéroarylalkyle ou cycloalkyle; et les substituants restants sont tels que définis dans le descriptif. L'invention concerne aussi des composés dans lesquels R?8¿ désigne H et la chaîne alkyle entre le groupe amide et le groupe imidazole R?13¿ n'est pas substituée. L'invention concerne encore un procédé de traitement du cancer et un procédé d'inhibition de la farnésyl protéine transférase utilisant les composés faisant l'objet de cette invention.
CA002354779A 1998-12-18 1999-12-16 Inhibiteurs de la farnesyl proteine transferase tryciclique Abandoned CA2354779A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18
US09/216,398 1998-12-18
PCT/US1999/027939 WO2000037459A1 (fr) 1998-12-18 1999-12-16 Inhibiteurs de la farnesyl proteine transferase tryciclique

Publications (1)

Publication Number Publication Date
CA2354779A1 true CA2354779A1 (fr) 2000-06-29

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002354779A Abandoned CA2354779A1 (fr) 1998-12-18 1999-12-16 Inhibiteurs de la farnesyl proteine transferase tryciclique

Country Status (20)

Country Link
EP (1) EP1140902A1 (fr)
JP (1) JP2002533336A (fr)
KR (1) KR20010081116A (fr)
CN (1) CN1326850C (fr)
AR (1) AR021718A1 (fr)
AU (1) AU776558B2 (fr)
BR (1) BR9916314A (fr)
CA (1) CA2354779A1 (fr)
CO (1) CO5160350A1 (fr)
CZ (1) CZ20011950A3 (fr)
HU (1) HUP0202152A2 (fr)
IL (1) IL143408A0 (fr)
NO (1) NO20012961L (fr)
NZ (1) NZ511878A (fr)
PE (1) PE20001342A1 (fr)
PL (1) PL348293A1 (fr)
SK (1) SK7592001A3 (fr)
TR (1) TR200101755T2 (fr)
WO (1) WO2000037459A1 (fr)
ZA (1) ZA200104233B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021718A1 (es) 1998-12-18 2002-07-31 Schering Corp Inhibidores de transferasa de proteina farnesilo.
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
AU2002236813A1 (en) 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
WO2002080895A2 (fr) * 2001-04-06 2002-10-17 Schering Corporation Traitements antipaludiques comprenant l'administration d'inhibiteurs de la fasnesyl proteine transferase
CN101115486A (zh) 2004-12-13 2008-01-30 先灵公司 新的法呢基蛋白转移酶抑制剂及其治疗癌症的用途
WO2006065794A1 (fr) * 2004-12-14 2006-06-22 Schering Corporation Inhibiteurs de farnésyl protéine transférase et méthodes de traitement de maladies proliférantes
EP1973882A1 (fr) * 2006-01-19 2008-10-01 Schering Corporation Dérivés de pipérazine en tant qu'inhibiteurs de farnésyl transférase
WO2015143188A1 (fr) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. 2-(2,4-difluorophényl)-1,1-difluoro-1-(pyridin-2-yl 5-substitué)-3-(1h-tétrazol-1-yl)propan-2-ols et procédés pour les préparer
MX2016012060A (es) 2014-03-19 2017-01-19 Viamet Pharmaceuticals Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
AU753658B2 (en) * 1997-06-17 2002-10-24 Pharmacopeia, Inc. Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
AR021718A1 (es) 1998-12-18 2002-07-31 Schering Corp Inhibidores de transferasa de proteina farnesilo.

Also Published As

Publication number Publication date
NO20012961L (no) 2001-08-16
CO5160350A1 (es) 2002-05-30
SK7592001A3 (en) 2002-03-05
HUP0202152A2 (en) 2002-10-28
ZA200104233B (en) 2002-08-22
PL348293A1 (en) 2002-05-20
PE20001342A1 (es) 2000-12-09
NZ511878A (en) 2003-10-31
NO20012961D0 (no) 2001-06-15
IL143408A0 (en) 2002-04-21
CN1326850C (zh) 2007-07-18
JP2002533336A (ja) 2002-10-08
AU776558B2 (en) 2004-09-16
CN1334811A (zh) 2002-02-06
TR200101755T2 (tr) 2001-09-21
AU2030700A (en) 2000-07-12
AR021718A1 (es) 2002-07-31
WO2000037459A1 (fr) 2000-06-29
EP1140902A1 (fr) 2001-10-10
BR9916314A (pt) 2001-10-02
KR20010081116A (ko) 2001-08-27
CZ20011950A3 (cs) 2001-12-12

Similar Documents

Publication Publication Date Title
US6372747B1 (en) Farnesyl protein transferase inhibitors
US6239140B1 (en) Compounds useful for inhibition of farnesyl protein transferase
US6124295A (en) Compounds useful for inhibition of farnesyl protein transferase
CA2354774C (fr) Inhibiteurs de la farnesyl proteine transferase
EP0819120A1 (fr) Composes tricycliques utiles a l'inhibition de la transferase de proteine farnesyle
CA2354779A1 (fr) Inhibiteurs de la farnesyl proteine transferase tryciclique
EP0989983B1 (fr) Composes a base de cycloheptane benzpyrido servant d'inhibiteurs de farnesyl proteine transferase
EP0927181A1 (fr) Composes tricycliques servant a inhiber la farnesyl-proteine transferase
EP0931079A1 (fr) Derives substitues de la benzocycloheptapyridine servant a inhiber la farnesyl-proteine transferase
EP0741722B1 (fr) Derives de triazole
US6689789B2 (en) Compounds useful for inhibition of farnesyl protein transferase
JP2002504147A (ja) ファルネシルタンパク質トランスフェラーゼの阻害に有用なベンゾ(5,6)シクロヘプタ(1,2−b)ピリジン誘導体
CA2293373C (fr) Derives de benzo(5,6)cyclohepta(1,2b)pyridine s'utilisant comme inhibiteurs de transferase de proteine de farnesyl
EP0927179B1 (fr) Derives substitues de la benzocycloheptapyridine utiles pour l'inhibition de la farnesyl transferase
MXPA01006241A (en) Tricyclic farnesyl protein transferase inhibitors
EP0989981A1 (fr) Nouveaux composes tricycliques de phenyle substitues inhibiteurs de farnesyl proteine transferase
MXPA97007232A (en) Triciaclic compounds of amida and urea, useful for inhibition of the function of protein g and for the treatment of proliferati diseases

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued